Redefining epilepsy monitoring
Epiminder introduces Minder®, the first FDA-authorised* implantable continuous EEG monitoring (iCEM®) system, designed for continuous monitoring of brain activity. This innovative solution empowers patients and healthcare professionals in the management of drug-resistant epilepsy.
Introducing Minder
continuous EEG monitoring
Minder is transforming epilepsy care through continuous long-term EEG monitoring.
Extended monitoring window
Minder delivers accurate data and extends the monitoring window from days with scalp EEGs to months or even years.
Enhanced treatment planning
Minder offers the possibility of addressing the current diagnostic limitations through high-quality signal capture and actionable information regarding seizures and other EEG events.
Life uninterrupted
Patients maintain normal daily activities while collecting critical EEG data.
Remote care capabilities
Facilitates remote monitoring to aid the care of patients and regular clinical assessment.
Understanding the global impact of epilepsy
Epilepsy affects over 52 million people worldwide, with 30-36%, or around 1.1 million adults in the US, experiencing drug-resistant epilepsy. The Minder system offers a revolutionary solution for continuous monitoring, empowering patients and healthcare providers alike.
52 million
people globally are affected by epilepsy
30-36%
experience drug-resistant forms of epilepsy
We have a commitment to improving the lives of those living with epilepsy
Integrity in patient care
We prioritise honesty and transparency in all our interactions with healthcare professionals and patients.
Innovation grounded in clinical evidence
Our solutions are developed based on rigorous scientific research and validation.
Empowerment through actionable data
We provide insights that allow physicians to help patients take control of their health.
Collaboration with the global epilepsy community
Together, we strive to advance epilepsy care and support.
Discover the future of epilepsy monitoring
Discover how Minder revolutionises epilepsy treatment in individuals with drug-resistant epilepsy through continuous monitoring.